Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDL NYSE:FRX TSE:ITH NASDAQ:MDNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDLCardiol Therapeutics$1.38-7.4%$1.36$0.77▼$2.63$123.18M1.05367,737 shs795,076 shsFRXForest Road Acquisition$10.30$9.72▼$18.20$450MN/A2.07 million shs40,482 shsITHInternational Tower Hill MinesC$1.56C$1.33C$0.57▼C$1.67C$219.02M1.1731,297 shs5,450 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDLCardiol Therapeutics-7.38%-4.17%-0.72%+21.05%-36.11%FRXForest Road Acquisition0.00%0.00%0.00%0.00%0.00%ITHInternational Tower Hill Mines0.00%+1.30%+26.83%+64.21%+155.74%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDLCardiol Therapeutics1.9453 of 5 stars3.74.00.00.00.00.00.6FRXForest Road AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/AN/AN/AN/AMDNAMedicenna Therapeutics1.3871 of 5 stars3.50.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDLCardiol Therapeutics 3.33Buy$8.00479.71% UpsideFRXForest Road Acquisition 0.00N/AN/AN/AITHInternational Tower Hill Mines 0.00N/AN/AN/AMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideCurrent Analyst Ratings BreakdownLatest MDNA, ITH, FRX, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025CRDLCardiol TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/AFRXForest Road AcquisitionN/AN/AN/AN/A$0.56 per shareN/AITHInternational Tower Hill MinesN/AN/AC$0.07 per share22.50C$0.29 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-209.63%-141.09%8/11/2025 (Estimated)FRXForest Road Acquisition-$7.92MN/A0.00N/AN/AN/AN/AN/AN/AITHInternational Tower Hill Mines-C$2.36M-C$0.02N/A∞N/AN/A-5.82%-3.65%N/AMDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ALatest MDNA, ITH, FRX, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025CRDLCardiol Therapeutics-$0.11N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDLCardiol TherapeuticsN/AN/AN/AN/AN/AFRXForest Road AcquisitionN/AN/AN/AN/AN/AITHInternational Tower Hill MinesN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDLCardiol Therapeutics0.013.263.26FRXForest Road AcquisitionN/A0.370.37ITHInternational Tower Hill MinesN/A10.3730.48MDNAMedicenna TherapeuticsN/A9.579.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDLCardiol Therapeutics12.49%FRXForest Road AcquisitionN/AITHInternational Tower Hill Mines71.80%MDNAMedicenna Therapeutics12.38%Insider OwnershipCompanyInsider OwnershipCRDLCardiol Therapeutics5.25%FRXForest Road AcquisitionN/AITHInternational Tower Hill Mines0.51%MDNAMedicenna Therapeutics33.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDLCardiol Therapeutics2082.68 million78.31 millionNot OptionableFRXForest Road AcquisitionN/A37.50 millionN/ANot OptionableITHInternational Tower Hill Mines220140.40 millionN/ANot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableMDNA, ITH, FRX, and CRDL HeadlinesRecent News About These CompaniesMedicenna Therapeutics Reports First Quarter Fiscal 2026 Financial Results and Operational HighlightsAugust 1 at 8:04 AM | globenewswire.comMedicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational HighlightsJune 26, 2025 | globenewswire.comMedicenna Therapeutics With Founder, Chairman, President & CEO, Dr. Fahar MerchantMay 14, 2025 | msn.comMedicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceApril 22, 2025 | markets.businessinsider.comMedicenna Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (MDNA)February 23, 2025 | theglobeandmail.comMedicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025February 5, 2025 | globenewswire.comThese TSX stocks saw more gains in 2024 than all the others, so farDecember 27, 2024 | msn.comMedicenna’s MDNA11 Shows Promise in Cancer TreatmentDecember 13, 2024 | tipranks.comMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)December 13, 2024 | globenewswire.comMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 StudyDecember 5, 2024 | globenewswire.comUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge ConferenceNovember 27, 2024 | financialpost.comFMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)November 25, 2024 | finance.yahoo.comMedicenna Showcases Promising Results and Strong FinancialsNovember 16, 2024 | markets.businessinsider.comMedicenna to Present Innovative Cancer Data at ConferencesNovember 13, 2024 | markets.businessinsider.comMedicenna announces single-agent activity of MDNA11 from dose expansion cohortNovember 11, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Buy Rating for Medicenna Therapeutics’ MDNA11November 11, 2024 | markets.businessinsider.comMedicenna Announces Breakthroughs in Cancer TreatmentNovember 9, 2024 | markets.businessinsider.comMedicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)October 4, 2024 | markets.businessinsider.com3 TSX Growth Stocks To Watch With Up To 39% Insider OwnershipSeptember 24, 2024 | finance.yahoo.comMedicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy ConferenceAugust 27, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonPalantir’s Revenue Surge to $1B: Growth vs. ValuationBy Chris Markoch | July 9, 2025View Palantir’s Revenue Surge to $1B: Growth vs. ValuationThese 3 Rare Earth Stocks Are Surging Alongside MP MaterialsBy Leo Miller | July 19, 2025View These 3 Rare Earth Stocks Are Surging Alongside MP MaterialsJoby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?By Jeffrey Neal Johnson | July 14, 2025View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?Rivian Stock Rallies as Robotaxi Buzz BuildsBy Gabriel Osorio-Mazilli | July 24, 2025View Rivian Stock Rallies as Robotaxi Buzz BuildsMDNA, ITH, FRX, and CRDL Company DescriptionsCardiol Therapeutics NASDAQ:CRDL$1.38 -0.11 (-7.38%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.40 +0.02 (+1.45%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Forest Road Acquisition NYSE:FRXForest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.International Tower Hill Mines TSE:ITHC$1.56 0.00 (0.00%) As of 08/1/2025 03:59 PM EasternInternational Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an advanced stage exploration project namely the Livengood Gold Project. It is located approximately 70 miles northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska mental health trust, a number of smaller private mineral leases, Alaska state mining claims purchased or located by the company and patented ground held by the company.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
